Patient-derived organoids (PDOs), including those from tumors, are implemented as predictive models of patient responses to drugs and therapies. Incorporation of the BioAssembly ™ platform has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback